This segment focuses on the research, development, and commercialization of targeted inhibitors for the treatment of hematologic and solid cancers. Key activities include the development of vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), currently in Phase 1b/2 clinical trials for chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies. The segment also includes preclinical studies of SNS-510 for solid tumors and hematologic malignancies, as well as partnered programs like TAK-580, a pan-Raf inhibitor in Phase 1 trials for pediatric low-grade glioma, and vosaroxin, an anti-cancer quinolone derivative. The segment leverages small molecule drug discovery and clinical trial expertise to address unmet needs in cancer treatment, aiming to improve patient outcomes through targeted therapies. Partnerships with companies like Biogen Idec and Takeda Pharmaceutical Company are crucial for expanding the pipeline and market reach. Future growth will depend on successful clinical trial results and regulatory approvals for lead product candidates.